A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats

Artery Research

Volumn 2, Issue 4, 2008, Pages 138-147

  Kohn, Michael H ^a   Price, Roger E ^b   Pelz, Hans Joachim ^c  

^a RICE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Vertebrate Research   (Germany)

Author keywords

Aorta; Mineralization; Renal artery; Urolith; Vitamin K epoxide reductase; Warfarin

Indexed keywords

MENADIONE EPOXIDE; OXIDOREDUCTASE; WARFARIN;

ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL CALCIFICATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEART; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; KIDNEY; MALE; MINERALIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; VALIDATION PROCESS; VKORC1 GENE;

EID: 56949090442     PISSN: 18729312     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.artres.2008.09.002     Document Type: Article

References (62)

1. Stahmann M.A., Huebner C.F., and Link K.P. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem 138 5 (1941) 513-527
2. Boyle C.M. Case of apparent resistance of Rattus norvegicus Berkenhout to anticoagulant poisons. Nature 188 (1960) 517
3. Lund M. Resistance to warfarin in common rat. Nature 203 494 (1964) 778
4. Greaves J.H., and Ayres P. Heritable resistance to warfarin in rats. Nature 215 5103 (1967) 877-878
5. Bell R.G., and Caldwell P.T. Mechanism of warfarin resistance - metabolism of vitamin-K1. Biochemistry 12 9 (1973) 1759-1762
6. Fasco M.J., Hildebrandt E.F., and Suttie J.W. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 257 19 (1982) 11210-11212
7. Hildebrandt E.F., Preusch P.C., Patterson J.L., and Suttie J.W. Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes. Arch Biochem Biophys 228 2 (1984) 480-492
8. MacNicoll A.D. A comparison of warfarin resistance and liver microsomal vitamin K epoxide reductase activity in rats. Biochim Biophys Acta 840 1 (1985) 13-20
9. Kohn M.H., and Pelz J.H. Genomic assignment of the warfarin resistance locus, Rw, in the rat. Mamm Genome 10 7 (1999) 696-698
10. Kohn M.H., and Pelz H.J. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood 96 5 (2000) 1996-1998
11. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.-J., et al. Mutations in Vkorc1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 6974 (2004) 537-541
12. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 6974 (2004) 541-544
13. Wallin R., and Hutson S.M. Warfarin and the vitamin K-dependent gamma-carboxylation system. Trends Mol Med 10 7 (2004) 299-302
14. Stafford D.W. The vitamin K cycle. J Thromb Haemost 3 8 (2005) 1873-1878
15. Suttie J.W. Warfarin and vitamin-K. Clin Cardiol 13 4 (1990) 16-18
16. Scully M.F. Warfarin therapy: rat poison and the prevention of thrombosis. The Biochemist 24 (2002) 15-17
17. D'Andrea G., D'Ambrosio R.L., Di Perna P., Chetta M., Santacroce R., Brancaccio V., et al. A polymorphism in the Vkorc1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 2 (2005) 645-649
18. Li T., Lange L.A., Li X., Susswein L., Bryant B., Malone R., et al. Polymorphisms in the Vkorc1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 43 9 (2006) 740-744
19. Gage B.F., and Lesko L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 25 (2008) 45-51
20. Schurgers L.J., Aebert H., Vermeer C., Bultmann B., and Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease?. Blood 104 10 (2004) 3231-3232
21. Fregin A., Rost S., Wolz W., Krebsova A., Muller C.R., and Oldenburg J. Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. Blood 100 9 (2002) 3229-3232
22. Pelz H.J., Rost S., Hunerberg M., Fregin A., Heiberg A.C., Baert K., et al. The genetic basis of resistance to anticoagulants in rodents. Genetics 170 4 (2005) 1839-1847
23. Schurgers L.J., Dissel P.E., Spronk H.M., Soute B.A., Dhore C.R., Cleutjens J.P., et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. Z Kardiol 90 Suppl. 3 (2001) III/57-III/63
24. Price P.A., Faus S.A., and Williamson M.K. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20 2 (2000) 317-327
25. Shearer M.J. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 3 6 (2000) 433-438
26. Price P.A., Buckley J.R., June H.H., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. J Bone Miner Res 16 (2001) S157-S158
27. Wallin R., Wajih N., Greenwood G.T., and Sane D.C. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 21 4 (2001) 274-301
28. Erkkila A.T., and Booth S.L. Vitamin K intake and atherosclerosis. Curr Opin Lipidol 19 (2008) 39-42
29. Price P.A., Faus S.A., and Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 18 9 (1998) 1400-1407
30. Howe A.M., and Webster W.S. Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol 81 1 (2000) 51-56
31. Price P.A., Patel R., and Alagao F.C. Matrix Gla protein specifically inhibits calcification of human aortic elastin in vitro. Arterioscler Thromb Vasc Biol 21 4 (2001) 703-708
32. Shanahan C.M., Proudfoot D., Farzaneh-Far A., and Weissberg P.L. The role of Gla proteins in vascular calcification. Crit Rev Eukaryot Gene Expr 8 3-4 (1998) 357-375
33. Alagao F.C., Patel R., and Price P.A. Matrix Gla protein specifically inhibits calcification of human aortic elastin in vitro. J Bone Miner Res 15 (2000) S208
34. Bostrom K., and Demer L.L. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr 10 2 (2000) 151-158
35. Braam L., Dissel P., Gijsbers B., Spronk H.M.H., Hamulyak K., Soute B.A.M., et al. Assay for human matrix Gla protein in serum - potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 20 5 (2000) 1257-1261
36. Canfield A.E., Doherty M.J., Kelly V., Newman B., Farrington C., Grant M.E., et al. Matrix Gla protein is differentially expressed during the deposition of a calcified matrix by vascular pericytes. FEBS Lett 487 2 (2000) 267-271
37. Wallin R., Cain D., Hutson S.M., Sane D.C., and Loeser R. Modulation of the binding of matrix Gla protein (MGP) to bone morphogenetic protein-2 (BMP-2). Thromb Haemost 84 6 (2000) 1039-1044
38. Dhore C., Cleutjens J., Kitslaar P., Tordoir J., Soute B., Vermeer C., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 12 (2001) 1998-2003
39. Farzaneh-Far A., Weissberg P.L., Proudfoot D., and Shanahan C.M. Transcriptional regulation of matrix Gla protein. Z Kardiol 90 Suppl. 3 (2001) 38-42
40. Wang Y., and Bostrom K.I. Matrix Gla protein binds bone morphogenetic protein-2, possible mechanism in vascular calcification. Arterioscler Thromb Vasc Biol 21 4 (2001) 702-708
41. Whittaker P., Donovan J.L., and Przyklenk K. Long-term warfarin therapy is associated with tissue calcification. J Thromb Thrombolysis 25 (2008) 125-128
42. Herrmann S.M., Whatling C., Brand E., Nicaud V., Gariepy J., Simon A., et al. Genetic polymorphisms in the matrix Gla protein are associated with calcification, atherosclerosis and myocardial infarction. Nieren Hochdruck 30 5 (2001) 193-195
43. Wang Y.B., Zhang W.L., Zhang Y.H., Yang Y.J., Sun L.Z., Hu S.S., et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 113 12 (2006) 1615-1621
44. Jackson W.B. Case histories of anticoagulant resistance. Committee on Strategies for the Management of Pesticide Resistant Pest Populations, National Research Council, editor. Pesticide resistance strategies and tactics for management (1986), National Academy Press, Washington DC
45. Pelz H.J., Rost S., and Muller C.R. DNA-based field monitoring of warfarin resistance in rats (Rattus norvegicus). Intl J Pest Management 53 (2007) 281-284
46. Bishop J.A., Hartley D.J., and Partridge G.G. Population-dynamics of genetically determined resistance to warfarin in Rattus norvegicus from Mid Wales. Heredity 39 12 (1977) 389-398
47. Partridge G.G. Relative fitness of genotypes in a population of Rattus norvegicus polymorphic for warfarin resistance. Heredity 43 10 (1979) 239-246
48. Berdoy M., and Smith P. Arms-race and rat race - adaptations against poisoning in the brown rat. Rev Ecol-Terre Vie 48 2 (1993) 215-228
49. Kohn M.H., Pelz H.J., and Wayne R.K. Natural selection mapping of the warfarin-resistance gene. Proc Natl Acad Sci U S A 97 14 (2000) 7911-7915
50. Greaves J.H., and Ayres P.B. Unifactorial inheritance of warfarin resistance in Rattus norvegicus from Denmark. Genet Res 29 3 (1977) 215-222
51. Smith P., Townsend M.G., and Smith R.H. A cost of resistance in the brown rat - reduced growth-rate in warfarin-resistant lines. Funct Ecol 5 3 (1991) 441-447
52. Partridge G.G. The vitamin-K requirements of wild Brown rats (Rattus norvegicus) resistant to warfarin. Comp Biochem Physiol 66 1 (1980) 3-7
53. Greaves J.H., Redfern R., Ayres P.B., and Gill J.E. Warfarin resistance - balanced polymorphism in Norway rat. Genet Res 30 3 (1977) 257-263
54. Smith P., Berdoy M., and Smith R.H. Body-weight and social dominance in anticoagulant-resistant rats. Crop Prot 13 4 (1994) 311-315
55. Pelz H.J., Hanisch D., and Lauenstein G. Resistance to anticoagulant rodenticides in Germany and future strategies to control Rattus norvegicus. Pestic Sci 43 1 (1995) 61-67
56. Pelz H.J., and Klemann N. Rat control strategies in organic pig and poultry production with special reference to rodenticide resistance and feeding behaviour. Njas-Wageningen J Life Sci 52 2 (2004) 173-184
57. Rost S., Fregin A., Hunerberg M., Bevans C.G., Muller C.R., and Oldenburg J. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1-evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost 94 4 (2005) 780-786
58. Kohn M.H., Pelz H.J., and Wayne R.K. Locus-specific genetic differentiation at Rw among warfarin-resistant rat (Rattus norvegicus) populations. Genetics 164 3 (2003) 1055-1070
59. Yasui T., Fujita K., Sasaki S., Sato M., Sugimoto M., Hirota S., et al. Expression of bone matrix proteins in urolithiasis model rats. Urol Res 27 4 (1999) 255-261
60. Greaves J.H., and Ayres P.B. Multiple allelism at the locus controlling warfarin resistance in the Norway rat. Genet Res 40 1 (1982) 59-64
61. Smith P., Berdoy M., Smith R.H., and Macdonald D.W. A new aspect of warfarin resistance in wild rats - benefits in the absence of poison. Funct Ecol 7 2 (1993) 190-194
62. Markussen M.D.K., Heiberg A.C., Nielsen R., and Leirs H. Vitamin K requirement in Danish anticoagulant-resistant Norway rats (Rattus norvegicus). Pest Manag Sci 59 8 (2003) 913-920